Audentes Therapeutics, Inc. Operating Cash Flow
Audentes Therapeutics, Inc. reported Operating Cash Flow of -$118.92 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2019-11-07
- Audentes Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2019-09-30 was -$35.87M.
- Audentes Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2019-06-30 was -$40.82M.
- Audentes Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2019-03-31 was -$42.22M.
- Audentes Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2018-12-31 was -$28.48M.
- Audentes Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2018 was -$107.98M.
- Audentes Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2017 was -$84.56M.
- Audentes Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2016 was -$48.93M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2019-09-30 | -$35.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$76.70M derived: sum of 2 quarters · filed 2019-11-07 | -$118.92M 10-Q · filed 2019-11-07 | -$147.40M derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-06-30 | -$40.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$83.04M 10-Q · filed 2019-08-07 | -$111.53M derived: sum of 3 quarters · filed 2019-08-07 | -$143.08M derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-03-31 | -$42.22M 10-Q · filed 2019-05-08 | -$70.70M derived: sum of 2 quarters · filed 2019-05-08 | -$102.25M derived: sum of 3 quarters · filed 2019-11-07 | -$125.61M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-12-31 | -$28.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$60.03M derived: sum of 2 quarters · filed 2019-11-07 | -$83.39M derived: sum of 3 quarters · filed 2019-11-07 | -$107.98M 10-K · filed 2019-03-01 |
| 2018-09-30 | -$31.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$54.90M derived: sum of 2 quarters · filed 2019-11-07 | -$79.50M 10-Q · filed 2019-11-07 | -$102.79M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | -$23.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$47.94M 10-Q · filed 2019-08-07 | -$71.24M derived: sum of 3 quarters · filed 2019-08-07 | -$94.22M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | -$24.59M 10-Q · filed 2019-05-08 | -$47.89M derived: sum of 2 quarters · filed 2019-05-08 | -$70.87M derived: sum of 3 quarters · filed 2019-05-08 | |
| 2017-12-31 | -$23.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$46.27M derived: sum of 2 quarters · filed 2019-03-01 | -$84.56M 10-K · filed 2019-03-01 | |
| 2017-09-30 | -$22.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$61.27M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$38.29M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | -$48.93M 10-K · filed 2019-03-01 |